Robust	O
diagnosis	O
of	O
Ewing	B-DISEASE
sarcoma	E-DISEASE
by	O
immunohistochemical	O
detection	O
of	O
super	O
-	O
enhancer	O
-	O
driven	O
EWSR1	O
-	O
ETS	O
targets	O
.	O
Ewing	B-DISEASE
sarcoma	E-DISEASE
is	O
an	O
undifferentiated	O
small	B-DISEASE
-	I-DISEASE
round	I-DISEASE
-	I-DISEASE
cell	I-DISEASE
sarcoma	E-DISEASE
.	O


Although	O
molecular	O
detection	O
of	O
pathognomonic	O
EWSR1	O
-	O
ETS	O
fusions	O
such	O
as	O
EWSR1	O
-	O
FLI1	O
enables	O
definitive	O
diagnosis	O
,	O
substantial	O
confusion	O
can	O
arise	O
if	O
molecular	O
diagnostics	O
are	O
unavailable	O
.	O


Diagnosis	O
based	O
on	O
the	O
conventional	O
immunohistochemical	O
marker	O
CD99	O
is	O
unreliable	O
due	O
to	O
its	O
abundant	O
expression	O
in	O
morphological	O
mimics	O
.	O


To	O
identify	O
novel	O
diagnostic	O
immunohistochemical	O
markers	O
for	O
Ewing	B-DISEASE
sarcoma	E-DISEASE
,	O
we	O
performed	O
comparative	O
expression	O
analyses	O
in	O
768	O
tumors	S-DISEASE
representing	O
21	O
entities	O
including	O
Ewing	B-DISEASE
-	I-DISEASE
like	I-DISEASE
sarcomas	E-DISEASE
,	O
which	O
confirmed	O
that	O
CIC	O
-	O
DUX4	O
-	O
,	O
BCOR	O
-	O
CCNB3	O
-	O
,	O
EWSR1	O
-	O
NFATc2	O
-	O
,	O
and	O
EWSR1	O
-	O
ETS	O
-	O
translocated	O
sarcomas	S-DISEASE
are	O
distinct	O
entities	O
,	O
and	O
revealed	O
that	O
ATP1A1	O
,	O
BCL11B	O
,	O
and	O
GLG1	O
constitute	O
specific	O
markers	O
for	O
Ewing	B-DISEASE
sarcoma	E-DISEASE
.	O


Their	O
high	O
expression	O
was	O
validated	O
by	O
immunohistochemistry	O
and	O
proved	O
to	O
depend	O
on	O
EWSR1	O
-	O
FLI1	O
-	O
binding	O
to	O
highly	O
active	O
proximal	O
super	O
-	O
enhancers	O
.	O


Automated	O
cut	O
-	O
off	O
-	O
finding	O
and	O
combination	O
-	O
testing	O
in	O
a	O
tissue	O
-	O
microarray	O
comprising	O
174	O
samples	O
demonstrated	O
that	O
detection	O
of	O
high	O
BCL11B	O
and	O
/	O
or	O
GLG1	O
expression	O
is	O
sufficient	O
to	O
reach	O
96	O
%	O
specificity	O
for	O
Ewing	B-DISEASE
sarcoma	E-DISEASE
.	O


While	O
88	O
%	O
of	O
tested	O
Ewing	B-DISEASE
-	I-DISEASE
like	I-DISEASE
sarcomas	E-DISEASE
displayed	O
strong	O
CD99	O
-	O
immunoreactivity	O
,	O
none	O
displayed	O
combined	O
strong	O
BCL11B	O
-	O
and	O
GLG1	O
-	O
immunoreactivity	O
.	O


Collectively	O
,	O
we	O
show	O
that	O
ATP1A1	O
,	O
BCL11B	O
,	O
and	O
GLG1	O
are	O
EWSR1	O
-	O
FLI1	O
targets	O
,	O
of	O
which	O
BCL11B	O
and	O
GLG1	O
offer	O
a	O
fast	O
,	O
simple	O
,	O
and	O
cost	O
-	O
efficient	O
way	O
to	O
diagnose	O
Ewing	B-DISEASE
sarcoma	E-DISEASE
by	O
immunohistochemistry	O
.	O


These	O
markers	O
may	O
significantly	O
reduce	O
the	O
number	O
of	O
misdiagnosed	O
patients	O
,	O
and	O
thus	O
improve	O
patient	O
care	O
.	O
